Lilly's 80-week phase 3 study of 1,152 adults, published in The Lancet, also showed HbA1c drops. Diarrhea and nausea were more common than on placebo.
Recap by typeshit. Full story at SciTechDaily.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Olhar Digital reports a Chinese approval for Wegovy, Novo Nordisk's semaglutide shot for weight loss. Few details beyond the headline were given.
The Pharma Letter looks at whether semaglutide in pill form could stand in for weekly shots for people trying to lose weight.
Loading…